Neurotech International
ASX:NTIMelbourne, Australia· Est.
Australian‑focused biotech developing a broad‑spectrum oral cannabinoid for paediatric neuroinflammatory disorders.
Is this your company? Claim your profile to update info and connect with investors.
Claim profileAI Company Overview
Australian‑focused biotech developing a broad‑spectrum oral cannabinoid for paediatric neuroinflammatory disorders.
NeurologyPediatrics
Technology Platform
Broad‑spectrum oral cannabinoid formulation (NTI164) delivering neuroprotective, anti‑inflammatory and neuromodulatory effects via the entourage effect.
Opportunities
Successful Phase III data could unlock regulatory approvals across major markets and enable partnerships or out‑licensing of NTI164 for multiple rare paediatric neuroinflammatory disorders.
Risk Factors
Reliance on a single drug candidate, regulatory uncertainty for cannabinoid medicines, and the need for additional capital to fund late‑stage trials.
Competitive Landscape
Few competitors target paediatric neuroinflammatory disorders with cannabinoid‑based therapies, giving Neurotech a differentiated niche despite broader competition from traditional neurology drugs.